No-see, no-handle needle

No mixing or reconstitution required

No need to dial a dose

Powerful efficacy, simply delivered

Once-weekly Trulicity provides powerful efficacy,* simply delivered for patients starting on injectable therapy1-3

Learn More

*In clinical studies, the range of A1C reduction from baseline was 0.7% to 1.6% for the 0.75 mg dose and 0.8% to 1.6% for the 1.5 mg dose.1,2 For more information on clinical trials, click here.

Recommended starting dose is 0.75 mg. Dose can be increased to 1.5 mg.

In a study, 99% of patients reported that overall, the Trulicity Pen was easy or very easy to use.3

Study description3

  • Patients with type 2 diabetes who were naïve to self-injection and injecting others (n=214) participated in a phase 3b, multicenter, open-label, single-arm, outpatient study on the safe and effective use of the Trulicity single-dose pen
  • The primary objective was to achieve a final injection success rate (proportion of patients who successfully complete injection) significantly greater than 80%
  • Patients were trained at baseline on proper self-injection technique with the pen
  • Final injection (4th weekly injection) success was observed in 99.1% [95% CI: 96.6% to 99.7%] (n=209) of patients (primary objective met). Success determined by evaluation of patients’ ability to accurately complete each step in the sequence of drug administration
  • After the final self-injection, patients completed a 12-item ease of use module (secondary endpoint). 208 (99%) out of 210 patients reported that overall, the single dose pen was “easy” or “very easy” to use

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Indication and Important Safety Information 
WARNING: POTENTIAL RISK OF THYROID TUMORS INCLUDING THYROID CANCER

Back to top